On May 13, 2024, Biocon Ltd informed the exchanges that it had signed a semi-exclusive distribution and supply agreement with Medix, a Mexico-based speciality pharmaceutical company. The agreement is to commercialise its vertically integrated drug product, Liraglutide (gSaxenda), used to treat chronic weight management. The company stated that, as per the terms of this agreement, …